anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD). The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.

ZULRESSO does not directly affect monoaminergic systems. Because of this and the comparatively low number of exposures to ZULRESSO, the risk of developing suicidal thoughts and behaviors with ZULRESSO is unknown. Consider changing the therapeutic regimen, including discontinuing ZULRESSO, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors.
BACKGROUND: Group A Streptococcus causes a variety of human infections, including the life-threatening necrotizing fasciitis, which may be ignored by the patient. From hours to days, the infection may progress from an apparently benign skin lesion, usually mistaken for a spider or insect bite, to a highly lethal disease. We present a case of 57-year-old male with skin lesions on swelling left upper limb.
METHODS AND RESULTS: The culture of secretion from epidermis and blood were positive for Group A Streptococcus (GAS), type β hemolytic streptococcus. Intensive anti-infection therapy was applied. However, the necrosis of the limb deteriorated rapidly. He died from multiple organ failure, streptococcal toxic shock syndrome (STSS) and disseminated intravascular coagulation 13 days later.
CONCLUSIONS: Necrotizing fasciitis is a rapidly progressive, destructive bacterial infection. Early recognition is the most important factor for survival.
The present disclosure describes ultrasound systems and methods configured to determine elasticity of target tissue. The system may comprise an ultrasound transducer configured to acquire echoes in response to ultrasound pulses emitted towards said tissue, which may comprise regions of increased stiffness. The system may further comprise a beamformer configured to control the transducer to transmit push pulses to the tissue to generate shear waves in the region of increased stiffness. The beamformer can be configured to control the transducer to transmit tracking pulses adjacent to the push pulses. The system may further comprise a processor configured to determine a displacement amplitude of the shear waves and generate a qualitative tissue elasticity map of the tissue based on the amplitude. The processor is capable of combining the qualitative map with a quantitative map of the same tissue and determining a boundary of the region of increased stiffness based on the combination.
Recent research suggests that parents and adolescents report an interest in doctors facilitating increased parent-teen communication about teen strengths. However, little research focuses on how to address this need in a primary care setting. Content from subject matter experts along with data gathered from parents and teens were used to develop a novel strengths-based intervention to be tested in primary care.

The study intervention being examined is called the Strengths Intervention Project and includes a written pamphlet, a guided discussion activity, in-person/phone health coaching, and in-person or mailed health care provider endorsement and key messaging. Measures will be collected at baseline pre-intervention (T1), in clinic or over the phone at the time of the intervention (T2), approximately two weeks post-intervention (T3), and approximately 2 months post-intervention (T4). Daily diaries will also be utilized twice to gather data pre- and post- intervention. We will measure feasibility of clinic implementation of intervention, as well as influence of intervention on parent-teen communication and adolescent outcomes.
The effects of IT and R.I.C.E. treatment on arm muscle performance in overhead athletes with elbow pain (EP) have been partially validated. However, there is a lack of research evidence regarding the efficacy of these two methods on arm muscle performance among swimmers with EP. The aim of this study was to investigate the trends and differences in the effects of IT and R.I.C.E. treatment on arm muscle performance among swimmers with EP. The main outcomes were the time effects and group effects of interventions on muscle voluntary contraction (MVC). Sixty elite freestyle swimmers from Tianjin, China, voluntarily participated in the study and completed a 10-week intervention program. Swimmers with EP in the IT group showed a positive trend in MVC, with an approximately 2% increase, whereas the MVC of subjects in the R.I.C.E. treatment group and control group decreased by approximately 4% and 5%, respectively. In comparison, the effects of the IT intervention on the MVC of the triceps and brachioradialis muscles in swimmers with EP were significant (p = 0.042 < 0.05, p = 0.027 < 0.05). The mean MVC value of the IT group (0.60) was greater than that of the other two groups (0.51, 0.50). IT has a beneficial impact on the MVC performance of the triceps and brachioradialis muscles in swimmers with EP. It is recommended that professionals consider incorporating IT into regular training routines to mitigate the risk of EP issues. Future research should examine the effectiveness of both interventions on hand-grip strength and completion time in 50-m freestyle swim drills in order for swimmers with EP to return to this sport.
INTRODUCTION: Plaque psoriasis, a chronic immune-mediated skin disorder, is characterized by well-demarcated erythematous plaques with silvery scales. This condition stems from complex interactions between genetic predisposition, immune dysregulation, and environmental triggers. Tapinarof downregulates the cytokine IL-17, diminishes the inflammatory infiltrate, and provides antioxidant properties while enhancing the expression of skin barrier proteins.
AREAS COVERED: This review begins by assessing tapinarof's mechanism in treating plaque psoriasis. Subsequently, it examines the effectiveness and safety of tapinarof 1% cream in adult patients.
EXPERT OPINION: Tapinarof 1% cream, which works by activating the aryl hydrocarbon receptor, is an FDA-approved treatment for adult plaque psoriasis. This therapy introduces a novel, nonsteroidal method for addressing inflammation and skin barrier issues, potentially serving as an alternative to conventional treatments. The once-daily, convenient cream formulation and favorable safety profile may enhance patient adherence, which is often poor with topical treatments. Tapinarof also maintains disease clearance for a mean of 4 months after treatment cessation.
This study will test the hypothesis that physical exercise training modifies alternative reward cue reactivity and cognitive control in tobacco use disorder and that these modifications mediate the effect of exercise on abstinence. Continued physical exercise training was shown to reduce tobacco consumption and prevent relapse in tobacco use disorder (TUD). However, the psychological and neural mechanisms through which exercise training exerts its effects on tobacco consumption are not clear. The aim of this project is to identify the effects of a 12-week aerobic exercise training in TUD and to test how these exercise-related changes may mediate the effect of exercise training on abstinence. Investigations will focus on two potential mechanisms of regaining control: (1) modifications of tobacco and alternative reward cue reactivity and (2) improvement of cognitive control. Two aspects of cognitive control will be addressed: inhibitory control and cognitive down-regulation of craving. It is expected, first, that exercise training (compared to standard treatment) leads to desensitization towards tobacco cues and sensitization towards alternative reward cues, reflected in altered craving and neural (fMRI) cue reactivity. Second, it is expected that exercise training will lead to increased cognitive control (i.e., inhibitory control and cognitive down-regulation of craving), reflected in increased activation of prefrontal control regions (fMRI). Third, it is expected that effects of exercise on abstinence will be mediated by sensitization towards alternative reward cues and enhanced cognitive control. In an exploratory manner, gender differences in the effects of exercise training will be studied. Understanding the psychological and neural underpinnings will help to optimize and individualize exercise trainings in TUD.
The present invention provides a chamber for implantation which has an immunoisolation membrane at the boundary between the inside and outside of the chamber for implantation. The immunoisolation membrane comprises a porous membrane. The maximum heat shrinkage of the porous membrane among heat shrinkages measured in the surface direction after immersion in water at 90º for three hours is 0.00-5.00%. The difference between the maximum heat shrinkage and the minimum heat shrinkage among the heat shrinkages measured in the surface direction is 0.00-1.30%. The present invention also provides a device for implantation wherein a biological constituent is included within the chamber for implantation. This chamber for implantation is highly durable and a biological constituent included therein can be maintained for a long time.
A microfiltration device for the filtration of coagula and microaggregates from blood and blood components. The device contains a filter chamber with attaching nozzle, a filter cone containing truncoconical filter elements arranged in cascade with diminishing pore size and diminishing surface area, a drip chamber and a tailpiece. The filter chamber and filter cones have different tapers and are at a specific distance apart, the taper of the filter cone from inlet to outlet being greater than the taper of the filter chamber. The filter cone has up to four filter elements, and a spacer which extends into the filter element of smallest pore size and surface area and supports same. Each of the filter elements has at least two opposed ribs running from the base to the apex of the truncated cone. The spacer is constructed such that it serves simultaneously for the support of the ribs and for the support of the filter fabric of the smallest filter element. The device has a capacity of less than 100 ml. It is intended for use in transfusions of preserved blood or blood components, especially massive transfusions.
The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.
The adequate preload target of fluid management has not yet been established during kidney transplantation. Traditionally, sufficient intravascular volume status has been recommended to maintain perfusion to renal graft. Stroke volume variation was reported to be superior to the traditional target of central venous pressure. In this regard, the investigators sought to compare the effect of two preload targets of stroke volume variation of ≤6% and ≤12% on the postoperative renal function in patients undergoing living donor kidney transplantation. Goal-directed fluid therapy will be performed in both groups to maintain adequate stroke volume, stroke volume variation, mean arterial pressure (or systemic vascular resistance) during kidney transplantation. Only the preload target for giving crystalloid during surgery will be different between groups.
Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention provides a cutin conditioning type skin whitening double-layer cleansing lotion. The cutin conditioning type skin whitening double-layer cleansing lotion is prepared from, by weight, 20% to 35% of grease, 1% to 15% of alcohol humectant, 5% to 20% of surface active agent, 0.25% to 2.5% of natural moisturizing factors (NMF), 0.1% to 0.5% of acid-base regulator, 5% to 20% of plant extract, 0.1% to 0.6% of corrosion remover, 0.1% to 0.4% of desensitizer and the balance deionized water. A weak acidic formula is adopted, cutin can be softened, the pH value of the skin can be regulated, the oil-water balance of the skin can be achieved, and the skin is restored to the healthy state. In the cleansing process, moisture of the skin is deeply conditioned and supplemented, the phenomena of pachulosis, dehydration and reluster are relieved, the cuticle achieves regular metabolism again, the skin is white and tender, aging is resisted, and the skin is made to be young again and release absolute light. In addition, plant extract is included in the cleansing lotion, so that the prepared cleansing lotion has the good effects of balancing grease secretion and whitening and brightening the skin color. Meanwhile, the invention provides a preparation method of the cleansing lotion.
Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion.
In a study of brinzolamide in lactating rats, decreases in body weight gain in offspring at an oral dose of 15 mg/kg/day (150 times the recommended human ophthalmic dose) were observed during lactation. No other effects were observed. However, following oral administration of 14C-brinzolamide to lactating rats, radioactivity was found in milk at concentrations below those in the blood and plasma. In animal studies, brimonidine was excreted in breast milk.  
  
It is not known whether brinzolamide and brimonidine tartrate are excreted in human milk following topical ocular administration. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Background: Posttraumatic stress disorder (PTSD) is a chronic psychiatric illness that is associated with significant suffering and disability in Veterans. Current treatment options are not fully effective for all Veterans, and even when they are effective in lowering total symptom burden, many Veterans continue to experience significant symptom burden and associated functional impairment. Total symptom burden and associated functional impairment is often particularly high for those with comorbid mild traumatic brain injury (mTBI). Methylphenidate (MPH) is a widely available psychostimulant medication with a long track record of safety, which has been used to improve cognitive functioning in attention deficit hyperactivity disorder (ADHD) and has also shown benefit for mood and cognitive functioning in studies of moderate or severe TBI and as augmentation in treatment-resistant major depressive disorder. In a small pilot study of the efficacy of MPH for subjective cognitive impairment associated with PTSD and/or mTBI, members of the research team found that MPH resulted in not only a significant improvement in subjective and objective measures of cognitive functioning, but also a significant decrease in symptoms of both depression and PTSD.

Methods: Here, the investigators propose to follow up this promising initial finding with an aggregated N-of-1 randomized placebo-controlled trial of MPH versus placebo (PBO) for PTSD and cognitive symptoms in Veterans with PTSD, with or without comorbid TBI. N=70 Veterans across two sites will each receive sequential 4-week periods of MPH and PBO, in randomized order and separated by a 1-week washout, for a total of 20 weeks. During this time, they will complete weekly or biweekly assessments. This trial design, which is particularly well-optimized for conditions in which a heterogeneous response to treatment is expected, will let us achieve a number of specific aims. First, the investigators will assess the efficacy of MPH compared to PBO for reducing PTSD and depression symptoms in Veterans with PTSD and neurocognitive complaints. Second, the investigators will assess the impact of MPH compared to PBO on neurocognitive functioning in this same population. And third, the investigators characterize the baseline predictors of treatment response to MPH in this population, including whether Veterans with a history of mTBI show greater average treatment response to MPH versus PBO. Finally, this trial design will also allow a systematic assessment of risks in this population, including the risk of discontinuation effects or loss of efficacy over time.

Significance: MPH represents a well-tolerated medication with a novel mechanism of action compared to the currently recommended and often ineffective pharmacologic treatments for PTSD and mTBI with associated cognitive complaints. If the results of this study support the use of MPH to decrease PTSD and neurocognitive symptoms in Veterans, it would provide an important new treatment option for Veterans with PTSD, which could be rapidly integrated into clinical practice.
PURPOSE:To provide a preservative for cosmetic, excellent in the safety, having a wide antimicrobial spectrum and capable of exhibiting a voider and stronger activity by using another preservative in combination. CONSTITUTION:This preservative for cosmetic contains a cationic chitosan derivative composed of a repeating unit of formula I [R1 is formula II (R3 to R5 are each an alkyl or an aralkyl; X is a halogen), H or acetyl; R2 is formula II or H]. This cationic chitosan derivative can be synthesized by partly substituting chitosan using a quaternary ammonium halide of formula III (R3 to R5 are each an alkyl or an aralkyl; R6 is formula IV or formula V). The degree (number of the group of formula II per the repeating unit) of substitution with the quaternary ammonium group of formula II can be controlled by the amount of added compound of formula III and the preferable range is 0.7 to 1.5. The mixture ratio of this Preservative to a cosmetic is 0.01 to 10wt.%, preferably 0.1to 1wt.%. As the preservative which can be used in combination with this preservative, a phenolic compound and/or its derivative, especially para-oxybenzoic acid ester and/or phenoxyethanol are preferable.
The invention described herein relates to colloidal particles useful for photoacoustic imaging. The particles comprise a photoacoustic imaging agent with an absorbance maximum or plateau in the range of wavelengths 700-1100 nm. The imaging agent also displays low optical absorbance at some wavelength in the range 700-1100 nm. This combination of high and low optical absorbance enables background subtraction in photoacoustic imaging applications. The imaging agent is an organic compound having low aqueous solubility so that it is stably encapsulated in the hydrophobic core of the particle. The particle is stabilized by a polymeric surface coating, and the polymeric stabilizing layer on the surface of the particle may contain targeting ligands for targeted diagnostics or therapeutic delivery. The particle core may also contain therapeutic agents or other imaging agents.
BACKGROUND: Radiation therapy is often indicated as part of the treatment for breast cancer and is therefore used frequently worldwide. Vasculopathy is a general term used to describe any condition that affects blood vessels. We present a case report of a patient who presented with vasculopathy as a rare late side effect of radiation therapy to the breast.
CASE PRESENTATION: This 66-year-old woman was initially treated with breast-conserving surgery for early-stage receptor-positive left breast carcinoma. She received postoperative radiation therapy and hormonal treatment with tamoxifen. She developed sudden spontaneous painless ecchymosis spread over the whole irradiated area 1.5 years after finishing her radiation therapy. Tumor relapse was excluded. There was no associated vasculitis. The cause was presumed to be multifactorial. She had a history of smoking and was known to have hyperlipidemia. She had undergone several surgical treatments at the left breast one year after her initial breast-conserving treatment and was taking tamoxifen. Anti-inflammatory medicine and treatments increasing local blood flow were prescribed. The ecchymosis resolved completely within one month.
CONCLUSIONS: Vasculopathy can occur as a rare late side effect of radiation therapy. It can be reversible. Prevention begins with carefully treating precipitating factors.
FIELD: medicine, vaccines. SUBSTANCE: invention relates to a method of live measles vaccine producing. Method involves the use of cultural virus-containing liquid (specific activity is 3.3 lg NCD 50 /0.5 ml, not less) as a liquid form. Live measles vaccine is mixed with gelatin and sorbitol as a stabilizing agent at ratio 1:1 at amount 10% of the live measles vaccine semifinished product, not less. For preparing the liposomal form virus-containing liquid and stabilizing agent are mixed with phosphatidylcholine and cholesterol at the definite ratio of components. Obtained vaccine is administrated in organism by oral route at the single dose 20 000 NCD 50  of measles virus, not less. Immunogenicity of vaccine is comparable with that of commercial injection form of the live measles vaccine but does not induce adverse reactions. EFFECT: improved method of preparing. 2 cl, 1 tbl, 6 ex
It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.